http://www.pharmaceutical-business-review.com Latest news from Pharmaceutical Business Review en-us Copyright 2008, Datamonitor Mon, 12 May 2008 14:58:00 GMT http://www.pharmaceutical-business-review.com/article_news.asp?guid=1758638C-814B-45E3-937A-6D380CF245A1 APP Pharmaceuticals, a manufacturer of multi-source and branded injectable pharmaceutical products, has reported net revenues of $148.1 million for the first quarter of 2008, an increase of 6%, compared with $140.3 million in the first quarter of 2007. Mon, 12 May 2008 14:58:00 GMT http://www.pharmaceutical-business-review.com/article_news.asp?guid=0D9E1915-BBDA-491A-93F9-F9AD5EBF0865 CorMatrix Cardiovascular has received 510(k) clearance from the FDA for its CorMatrix ECM for Cardiac Tissue Repair, which utilizes the company's proprietary ECM Technology. Mon, 12 May 2008 14:52:00 GMT http://www.pharmaceutical-business-review.com/article_news.asp?guid=5AB351EA-1930-43A7-BF9F-19EE2E8FD545 Enterix, a wholly-owned subsidiary of Quest Diagnostics, has announced the availability of the InSure Quik F I T fecal immunochemical test, a point-of-care version of the company's lab-based InSure FIT test that provides physicians with the sensitivity and specificity of the laboratory-based InSure FIT test. Mon, 12 May 2008 14:50:00 GMT http://www.pharmaceutical-business-review.com/article_news.asp?guid=5D2C7425-7350-4C0D-AAFD-30CA5026855B Atrium Medical has obtained US FDA 510(K) approval for two new Omega 3 surgical mesh products - C-QUR Edge V-Patch and C-QUR Lite V-Patch. Mon, 12 May 2008 14:49:00 GMT http://www.pharmaceutical-business-review.com/article_news.asp?guid=3667A633-BDE2-48C8-9ADA-9147996D2C17 Jazz Pharmaceuticals has entered into a committed equity financing facility with Kingsbridge Capital, a private investment group, in which Kingsbridge has committed to provide up to $75 million of capital during the next three years through the purchase of newly-issued shares of Jazz Pharmaceuticals's common stock. Mon, 12 May 2008 14:47:00 GMT http://www.pharmaceutical-business-review.com/article_news.asp?guid=A2C3EBB9-1CDC-4F2D-97D0-82403BDE533A Boston Scientific has announced that the Canadian Federal Court has issued judgment in a lawsuit in which Johnson & Johnson had accused the company's NIR stent of infringing two Johnson & Johnson Palmaz patents. Mon, 12 May 2008 14:44:00 GMT http://www.pharmaceutical-business-review.com/article_news.asp?guid=0FFD184B-4537-4E72-B0D2-0DEC88DC95EC Javelin Pharmaceuticals has received commitments from selected investors to purchase up to 11.45 million shares of its common stock at a purchase price of $2.41 per share. Mon, 12 May 2008 14:39:00 GMT http://www.pharmaceutical-business-review.com/article_news.asp?guid=75844C2B-4108-4D6B-98E6-046BFB8BFBBC Warner Chilcott has reported total revenues of $229.5 million for the quarter ended March 31, 2008, an increase of 5.1%, over the prior year quarter. Mon, 12 May 2008 14:38:00 GMT http://www.pharmaceutical-business-review.com/article_news.asp?guid=37C6684A-A459-4E39-9B87-D8FBC23ACF76 Repros Therapeutics has reported that its total revenues decreased 15% to $269,000 for the three-month period ended March 31, 2008 as compared to $318,000 for the same period of 2007 primarily due to lower cash balances. Mon, 12 May 2008 14:34:00 GMT http://www.pharmaceutical-business-review.com/article_news.asp?guid=CE5EDF81-6611-4D09-A5EF-031B8FDBF47A Affymax has reported a net loss of $15.6 million for the first quarter ended March 31, 2008 compared to a net loss of $7.2 million for the first quarter of 2007. Mon, 12 May 2008 14:32:00 GMT http://www.pharmaceutical-business-review.com/article_news.asp?guid=18D22A05-D218-413E-AC67-2DE43CC66911 Progenics Pharmaceuticals has reported a net loss of $15.5 million or $0.52 per share for the first quarter of 2008, compared to a net loss of $10.4 million or $0.40 per share for the first quarter of 2007. Mon, 12 May 2008 14:27:00 GMT http://www.pharmaceutical-business-review.com/article_news.asp?guid=4B5404BE-6958-46F2-AD63-8580B0BBBDF3 The FDA has approved a new formulation of the genetically engineered version of Factor VIIa, a plasma protein essential for the clotting of blood. The new formulation allows the product to be stored at room temperature for up to two years. Mon, 12 May 2008 14:26:00 GMT http://www.pharmaceutical-business-review.com/article_news.asp?guid=2E1ED08D-73BF-4E48-BD29-4A99527B9077 ABR-Affinity BioReagents, a global antibody manufacturer, has announced the finalization of new distribution agreements with LuBioScience, headquartered in Lucerne, Switzerland and Bio-Kasztel, located in Budapest, Hungary, further expanding its already extensive network of distribution partners in Europe. Mon, 12 May 2008 14:24:00 GMT http://www.pharmaceutical-business-review.com/article_news.asp?guid=64044C01-6384-4E1A-B9E2-899F208FE9C1 ProStrakan Group has announced positive results from the pivotal US clinical program on Fortigel for testosterone replacement therapy in hypogonadal men. Based on these results, ProStrakan expects to re-file Fortigel with the FDA in the third quarter of 2008. Mon, 12 May 2008 14:23:00 GMT http://www.pharmaceutical-business-review.com/article_news.asp?guid=8A8F07D6-5132-49E9-A609-ACEA282F8B81 Proteome Sciences has reported that it has been selected to participate as a partner in the E13.7 million Sens-it-iv Framework 6 EU program, the largest integrated project in the EU funding program, the aim of which is to develop 'in-vitro' alternatives to animal tests currently used for the risk assessment of potential skin or lung conditions. Mon, 12 May 2008 14:20:00 GMT http://www.pharmaceutical-business-review.com/article_news.asp?guid=EC7BFDB7-728F-45AE-B3B4-FC7F96721720 Medarex has initiated the Phase II clinical development program of MDX-1100, a fully human monoclonal antibody that targets CXCL10, in ulcerative colitis and rheumatoid arthritis. Mon, 12 May 2008 14:06:00 GMT http://www.pharmaceutical-business-review.com/article_news.asp?guid=F258916F-FAF4-46E4-AB68-A2E66DA911CD Specialty pharmaceutical firm Cytochroma has appointed Richard Wieland II as its new CFO. Mon, 12 May 2008 14:02:00 GMT http://www.pharmaceutical-business-review.com/article_news.asp?guid=74FF8E2F-4FA5-49B1-9C61-A7624B12C5CA Cardinal Health has completed the acquisition of assets of privately held Enturia, the manufacturer of infection prevention products sold under the ChloraPrep brand name. Mon, 12 May 2008 13:59:00 GMT http://www.pharmaceutical-business-review.com/article_news.asp?guid=8BE6CD47-1726-4CFF-83CE-64DA0D8102D5 Takeda Global R&D Center and Affymax have reported positive 12 month data from their ongoing Phase II trial evaluating the safety and tolerability of Hematide, an investigational drug in development for the treatment of anemia associated with chronic kidney disease. Mon, 12 May 2008 13:56:00 GMT http://www.pharmaceutical-business-review.com/article_news.asp?guid=98D9DA0C-0AF2-414B-8D0B-FF655832B378 Novadaq Technologies, a developer of real-time imaging and image guidance systems for use in the operating room, has announced that John Reidy, has been appointed CFO of the company, assuming the role on June 1, 2008. Mon, 12 May 2008 13:52:00 GMT